Business news – Page 65
-
Business
Merck & Co to buy Afferent for neurology drugs
Deal worth up to $1.25bn includes drug candidate for chronic coughs
-
BusinessJ&J to buy Vogue for haircare range
$3.3bn deal expands Johnson & Johnson’s consumer products segment
-
OpinionHow the chemical industry is voting in the EU referendum
UK trade bodies predominantly favour remaining in the EU
-
ResearchConnections in flow
MIT’s Klavs Jensen tells us how his research ranges in size from a chip, to a fridge to a shipping container
-
BusinessVertellus enters bankruptcy
Chemical maker files for Chapter 11 bankruptcy protection for its US operations and plans to auction the business
-
BusinessThermoFisher Scientific to buy electron microscope maker
Deal will expand lab equipment provider’s instrument portfolio for life and materials sciences
-
BusinessJazz Pharma buy out Celator in $1.5bn deal
Deal centres on promising leukaemia drug fast-tracked by the US Food and Drug Administration
-
BusinessFracking gets first UK approval for five years
Council says Third Energy can test existing borehole in North Yorkshire
-
NewsAkzoNobel sponsors colour garden at Chelsea Flower Show
Display celebrates plants that have been used historically to make dyes, and highlights a new project to capture nature’s structural colours in paint
-
BusinessIndia hit hard by US regulatory sanctions
Data integrity issues have led to punitive measures, but companies are taking measures to improve
-
BusinessUS tax rules force fertiliser merger to fall flat
CF Industries’ $8bn merger plan to relocate from US to Europe scuppered by regulatory changes
-
OpinionLet's see that again
Has chemistry evaded the reproducibility crises affecting other branches of science? Or is it just a question of scale, asks Derek Lowe
-
BusinessUS tax relief law benefits chemical makers
Bill provides mechanism to waive import tariffs on materials not available from domestic suppliers
-
BusinessMonsanto turns down Bayer offer
As global agrochemical companies consolidate, Monsanto rejects ‘inadequate’ $62bn offer from Bayer
-
NewsUS drug giant will no longer supply lethal injection drugs
With Pfizer’s exit no US-approved pharma firm will sell its drugs to be used in executions
-
BusinessWHO clarifies glyphosate risks
UN and WHO panel conclude the herbicide glyphosate is ‘unlikely’ to cause cancer at realistic exposure levels
-
-
BusinessMylan expands in dermatology
$1bn deal with Renaissance Acquisition Holdings brings 25 products and builds on Meda merger portfolio
-
BusinessPfizer to buy Anacor for eczema ointment
$5.2bn deal will bolster pharma giant’s inflammation and immunology drugs portfolio
-
Business
Honeywell spins off resins and chemicals unit
‘AdvanSix’ will separate by early 2017 and produce nylon, fertiliser and various chemical intermediates